Evoke Quick Ratio from 2010 to 2024

EVOK Stock  USD 4.89  0.01  0.20%   
Evoke Pharma Quick Ratio yearly trend continues to be quite stable with very little volatility. The value of Quick Ratio is projected to decrease to 1.99. Quick Ratio is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. View All Fundamentals
 
Quick Ratio  
First Reported
2010-12-31
Previous Quarter
2.09008962
Current Value
1.99
Quarterly Volatility
2.94988328
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 131.7 K, Interest Expense of 603.8 K or Selling General Administrative of 11.6 M, as well as many indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 45.05. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
  
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Latest Evoke Pharma's Quick Ratio Growth Pattern

Below is the plot of the Quick Ratio of Evoke Pharma over the last few years. It is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. Evoke Pharma's Quick Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evoke Pharma's overall financial position and show how it may be relating to other accounts over time.
Quick Ratio10 Years Trend
Very volatile
   Quick Ratio   
       Timeline  

Evoke Quick Ratio Regression Statistics

Arithmetic Mean4.41
Geometric Mean3.24
Coefficient Of Variation66.87
Mean Deviation2.46
Median3.46
Standard Deviation2.95
Sample Variance8.70
Range10.4889
R-Value(0.09)
Mean Square Error9.30
R-Squared0.01
Significance0.75
Slope(0.06)
Total Sum of Squares121.83

Evoke Quick Ratio History

2024 1.99
2023 2.09
2022 6.91
2021 7.38
2020 1.2
2019 3.1
2018 3.46

About Evoke Pharma Financial Statements

Evoke Pharma investors utilize fundamental indicators, such as Quick Ratio, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Quick Ratio 2.09  1.99 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.13)
Revenue Per Share
7.792
Quarterly Revenue Growth
0.698
Return On Assets
(0.34)
Return On Equity
(3.50)
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.